We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Hurel® Corporation Completes Investment from Johnston Associates

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Hurel Corporation has announced that Johnston Associates, Inc. of Princeton, New Jersey (“JAI”) has become a participating investor in the Company’s Series A-3 Preferred Stock financing. Hurel’s lead private equity investor, Spring Mountain Capital, LP, of New York, led the A-3 round.

“Johnston Associates is pleased to invest in Hurel, which is about to emerge as the leader in cell-based liver models,” Robert F. Johnston, JAI’s Managing Partner, said. “Hurel’s products have the capacity to improve and ultimately transform how preclinical drug discovery and general chemical testing are carried out. I’m looking forward to working with Hurel’s talented management team as they extend the commercial reach of their products and their company.”

Hurel CEO Robert Freedman commented, “As a founder of multiple, major biotech companies, Bob Johnston brings Hurel an immense resource of knowledge upon which we will be able to draw. It’s an honor and a pleasure to welcome Bob to Hurel’s investor family.”